{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T17:54:40Z","timestamp":1778608480106,"version":"3.51.4"},"reference-count":33,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To assess the prevalence, time of onset, risk factors, and outcome of avascular necrosis (AVN) of bone in patients with multiple myeloma undergoing antineoplastic therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>A total of 553 consecutive assessable patients were enrolled onto a treatment protocol consisting of dexamethasone-containing induction chemotherapy, autologous stem-cell transplantation, consolidation chemotherapy, and maintenance with interferon alfa. Patients were randomly assigned to receive thalidomide (269 patients) or no thalidomide (284 patients) throughout the study period.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>With a median follow-up of 33 months (range, 5 to 114 months), AVN of the femoral head(s) developed in 49 patients (9%). Median time to onset of AVN was 12 months (range, 2 to 41 months). Three risk factors for AVN were identified by multivariate analysis: cumulative dexamethasone dose (odds ratio [OR], 1.028; 95% CI, 1.012 to 1.044; P = .0006 [per 40 mg dexamethasone]), male sex (OR, 0.390; 95% CI, 0.192 to 0.790; P = .009), and younger age (OR, 0.961; 95% CI, 0.934 to 0.991 per year; P = .0122). Thalidomide-treated patients had a prevalence of AVN similar to that of the control group (8% v 10%, respectively; P = .58). AVN-related pain and limited range of motion of the affected joint were present in only nine and four patients, respectively, and four patients underwent hip replacement because of AVN. Fluorine-18 fluorodeoxyglucose positron emission tomography failed to detect abnormal uptake in the AVN-affected bones.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>AVN is a rare and usually asymptomatic complication during myeloma therapy. Cumulative dexamethasone dose, male sex, and younger age, but not thalidomide, increase the risk of AVN.<\/jats:p><\/jats:sec>","DOI":"10.1200\/jco.2005.11.676","type":"journal-article","created":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T03:44:08Z","timestamp":1118807048000},"page":"5217-5223","source":"Crossref","is-referenced-by-count":52,"title":["Avascular Necrosis of Femoral and\/or Humeral Heads in Multiple Myeloma: Results of a Prospective Study of Patients Treated With Dexamethasone-Based Regimens and High-Dose Chemotherapy"],"prefix":"10.1200","volume":"23","author":[{"given":"Giampaolo","family":"Talamo","sequence":"first","affiliation":[{"name":"From the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edgardo","family":"Angtuaco","sequence":"additional","affiliation":[{"name":"From the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald C.","family":"Walker","sequence":"additional","affiliation":[{"name":"From the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Dong","sequence":"additional","affiliation":[{"name":"From the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa H.","family":"Miceli","sequence":"additional","affiliation":[{"name":"From the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Zangari","sequence":"additional","affiliation":[{"name":"From the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Tricot","sequence":"additional","affiliation":[{"name":"From the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bart","family":"Barlogie","sequence":"additional","affiliation":[{"name":"From the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elias","family":"Anaissie","sequence":"additional","affiliation":[{"name":"From the Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2002.33724b"},{"key":"R2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10835"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Gillespy T III, Genant HK, Helms CA: Magnetic resonance imaging of osteonecrosis. Radiol Clin North Am 24:193,1986-208,","DOI":"10.1016\/S0033-8389(22)01071-5"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11373"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1262940.x"},{"key":"R6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1701374"},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1016\/S8756-3282(97)00219-6"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910801)68:3<655::AID-CNCR2820680336>3.0.CO;2-V"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9260(97)80253-X"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199607)52:3<184::AID-AJH8>3.0.CO;2-P"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Marymont JV, Kaufman EE: Osteonecrosis of bone associated with combination chemotherapy without corticosteroids. Clin Orthop Relat Res 204:150,1986-153,","DOI":"10.1097\/00003086-198603000-00016"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Virik K, Karapetis C, Droufakou S, et al: Avascular necrosis of bone: The hidden risk of glucocorticoids used as antiemetics in cancer chemotherapy. Int J Clin Pract 55:344,2001-345,","DOI":"10.1111\/j.1742-1241.2001.tb11055.x"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1159\/000203722"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1354\/vp.40-4-345"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.3.8048"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1172\/JCI2799"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Weinstein RS, Nicholas RW, Manolagas SC: Apoptosis of osteocytes in glucocorticoid-induced osteonecrosis of the hip. J Clin Endocrinol Metab 85:2907,2000-2912,","DOI":"10.1210\/jc.85.8.2907"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1007\/BF03165280"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-9877(97)90067-0"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-200101000-00019"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00386-X"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1016\/0960-0760(93)90141-I"},{"key":"R23","unstructured":"Mazieres B: Osteonecrosis, in Klippel J, Dieppe P (eds): Rheumatology . London, United Kingdom, Mosby, pp1,1998-47"},{"key":"R24","unstructured":"Calandriello B, Grassi G: Idiopathic osteonecrosis of the femoral head: Epidemiological and aetiological factors. Ital J Orthop Traumatol 8:9,1982-18,"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.322.7302.1589"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(90)90214-X"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"O'Brien TJ, Mack GR: Multifocal osteonecrosis after short-term high-dose corticosteroid therapy: A case report. Clin Orthop Relat Res 176,1992-179,","DOI":"10.1097\/00003086-199206000-00022"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Taylor LJ: Multifocal avascular necrosis after short-term high-dose steroid therapy: A report of three cases. J Bone Joint Surg Br 66:431,1984-433,","DOI":"10.1302\/0301-620X.66B3.6725356"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402139"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1359\/jbmr.2003.18.11.2016"},{"key":"R31","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.3.346"},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.99.141"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.147.1.67"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2005.11.676","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T11:22:38Z","timestamp":1683112958000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2005.11.676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":33,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2005,8,1]]}},"alternative-id":["10.1200\/JCO.2005.11.676"],"URL":"https:\/\/doi.org\/10.1200\/jco.2005.11.676","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,1]]}}}